Last reviewed · How we verify

Intragastric denatonium benzoate

Universitaire Ziekenhuizen KU Leuven · FDA-approved active Small molecule

Denatonium benzoate is a bitter-tasting compound administered intragastrically that triggers aversive taste responses to discourage accidental ingestion or promote satiety.

Denatonium benzoate is a bitter-tasting compound administered intragastrically that triggers aversive taste responses to discourage accidental ingestion or promote satiety. Used for Appetite suppression / weight management (investigational), Safety additive in pharmaceutical formulations to prevent accidental ingestion.

At a glance

Generic nameIntragastric denatonium benzoate
Also known asIG DB
SponsorUniversitaire Ziekenhuizen KU Leuven
Drug classBitter taste receptor agonist / Aversive agent
TargetBitter taste receptors (T2R family)
ModalitySmall molecule
Therapeutic areaGastroenterology / Obesity / Safety
PhaseFDA-approved

Mechanism of action

Denatonium benzoate is one of the most bitter substances known and activates bitter taste receptors (T2Rs) on the tongue and in the gastrointestinal tract. When administered intragastrically, it elicits a strong aversive gustatory response that can be used as a safety measure in pharmaceutical formulations or as a potential appetite-suppressing agent. The mechanism relies on the natural human rejection response to intensely bitter stimuli.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: